Lupin receives “A-” leadership rating from CDP in climate change and water security

This rating reflects Lupin's leadership in environmental transparency and performance

Health Minister inaugurates Second AIIMS Oncology Conclave at NCI-AIIMS, Jhajjar

ALPLA opens new manufacturing plant in Thailand

ALPLA is going to manufacture high-quality plastic bottles, preforms, matching closures and injection-molded parts in Chachoengsao using all core technologies

GSK’s Penmenvy approved by FDA to help protect against MenABCWY

Vaccine helps protect against five common disease-causing serogroups of Neisseria meningitidis (A, B, C, W and Y)

Sanofi updates on extraintestinal pathogenic E. coli vaccine phase 3 clinical study

No safety signals related to the vaccine candidate were identified

AbbVie Appoints CEO Robert A. Michael as Chairman of the Board of Directors

Richard A. Gonzalez to retire from the board of directors effective July 1, 2025

Lupin Q3 FY25 profit up 40% at Rs. 855 Cr

Revenue up 11% to Rs 5,768 crore as compared to Rs 5,197 crore

IOL Chemicals and Pharmaceuticals reports Q3 FY25 revenue at Rs. 527.37 Cr

Total Income during Q3 FY25 stood at Rs. 527.37 crore as compared to Rs. 528.77 crore in Q3 FY24

Utthunga partners with VindAir to advance smart solutions for pharma industry

The company will offer end-to-end services and solutions for the sector with a specific focus on sustainability

Lupin receives approval from USFDA for Ipratropium Bromide Nasal Solution

Ipratropium Bromide Nasal Solution is indicated for the symptomatic relief of rhinorrhea associated with allergic and nonallergic perennial rhinitis